BeOne Medicines Ltd. (ONC) Stock Analysis
Falling Knife setup · Temp Headwind edge
Healthcare · Biotechnology
Wait — supporting gate not met yet. Price is at or below entry $294.06 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Concentration risk — Product: BRUKINSA; Negative momentum.
BeOne Medicines discovers and commercializes oncology medicines globally, led by BRUKINSA (zanubrutinib), a BTK inhibitor approved in 77 markets, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in 51 markets. The company generated approximately $5.3 billion in total... Read more
Wait — supporting gate not met yet. Price is at or below entry $294.06 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Concentration risk — Product: BRUKINSA; Negative momentum. Chart setup: Death cross, below all MAs, RSI 22, MACD bearish. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.00, quality 7.5/10, growth 10.0/10). Score 6.5/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent developments
updated 2026-06-17Recent Developments — BeOne Medicines Ltd.
Latest news
- NEWS BeOne Medicines (ONC) Receives FDA Priority Review for Tevimbra Treatment - GuruFocus — GuruFocus positive
- NEWS U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA - Business Wire — Business Wire positive
- NEWS BeOne Medicines (ONC) Reveals Promising HERIZON-GEA-01 Trial Results - GuruFocus — GuruFocus positive
- NEWS BeOne Medicines (ONC) director sells ADS to satisfy tax withholding - Stock Titan — Stock Titan negative
- NEWS BeOne Medicines (ONC) director sells 212 ADS to cover tax withholding - Stock Titan — Stock Titan negative
Generated 2026-06-17T11:31:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductBRUKINSA10-K Item 1: 'total global revenue of approximately $5.3 billion ... BRUKINSA generated $3.9 billion in sales in 2025'
- MEDIUMGeographicChina10-K Item 1A: 'which could have a material adverse effect on our business, financial condition and results of operations in China'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait — supporting gate not met yet. Price is at or below entry $294.06 but weak momentum; below 200-day MA (death cross) still blocks BUY_NOW. Key risks: Concentration risk — Product: BRUKINSA; Negative momentum. Chart setup: Death cross, below all MAs, RSI 22, MACD bearish. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 0.00, quality 7.5/10, growth 10.0/10). Target $371.11 (+40.9%), stop $278.38 (−-5.4%), Setup A.R:R 9.8:1. Score 6.5/10, moderate confidence.
Take-profit target: $371.11 (+43.9% upside). Target $371.11 (+40.9%), stop $278.38 (−-5.4%), Setup A.R:R 9.8:1. Stop-loss: $278.38.
Concentration risk — Product: BRUKINSA; Negative momentum; Below 200-day MA.
BeOne Medicines Ltd. trades at a P/E of 59.8 (forward 27.2). TrendMatrix value score: 5.9/10. Verdict: Buy (Wait for Entry).
12 analysts cover ONC with a consensus score of 4.2/5. Average price target: $412.
What does BeOne Medicines Ltd. do?BeOne Medicines discovers and commercializes oncology medicines globally, led by BRUKINSA (zanubrutinib), a BTK...
BeOne Medicines discovers and commercializes oncology medicines globally, led by BRUKINSA (zanubrutinib), a BTK inhibitor approved in 77 markets, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in 51 markets. The company generated approximately $5.3 billion in total revenue in 2025, with BRUKINSA contributing $3.9 billion in sales, and employs nearly 12,000 people across research, clinical, and commercial operations.